Therapeutic Advances in Myelodysplastic Syndromes: From Investigation to Clinical Practice

Join us live in Chicago or online for this 1.5-hour, live interactive symposium focused on the latest advances in myelodysplastic syndromes. Experts will answer audience questions and discuss the latest evidence. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.


  • Welcome and Introduction
  • Risk Stratification in MDS
  • Strategies for Managing Very Low–Risk, Low-Risk, and Intermediate-Risk MDS
  • Latest Guidance on the Treatment of Higher-Risk MDS and Managing Relapsed/Refractory MDS
  • Summary
  • Audience Questions


Date / Time
Event Details


Program Director
Rami Komrokji, MD

Senior Member, Vice Chair
Malignant Hematology
Section Head
Leukemia and MDS
H. Lee Moffitt Cancer Center & Research Institute
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Goal Statement
The goal of this program is to improve the knowledge and competence of learners on current and emerging treatment options and the latest clinical data on lower-risk, intermediate-risk, and high-risk MDS.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with MDS.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate novel therapeutic options for managing MDS-related symptoms, which may include anemia, cytopenia, thrombocytopenia and/or neutropenia
  • Evaluate available clinical data and emerging treatment options for patients with lower-, intermediate-, or high-risk MDS
  • Plan evidence-based therapeutic strategies for patients with relapsed/refractory disease
  • Identify patients eligible for enrollment on clinical trials investigating novel therapeutic approaches for treating and managing MDS


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.